OncoSec Medical Inc (ONCSQ)

[guti]

The authors concluded that without IL-12 treatment, the human cells infiltrating the RMS tumors were immature NK cells and HLA class II-negative M2 macrophages that were permissive for tumor proliferation. Treatment with IL-12 drove development of M1 pro-inflammatory macrophages and up-regulated several receptors on NK cells required for their functionally maturity and ability to secrete IFN-g and TNF. The combination of IL-12 and IL-7 suppressed tumor cell proliferation but did not promote the human cytotoxic immune cell responses. Combining IL-12 with IL-2 also led to tumor senescence, but the infiltrating T and NK cells demonstrated cytotoxic activity that killed tumor cells and allowed 100% of the treated mice to survive. The tumor-bearing humanized mouse provides an excellent platform for evaluating the efficacy of biomolecules engineered to enhance anti-tumor human immune responses.

Exactly what Dr. Pierce has been saying, now let's see what happens when combined with anti PD-1.